Shares of Dr Reddy's Laboratories dropped 6% in early trade on Friday, a day after the company reported a third-quarter profit that fell short of market estimates due to lower sales and pricing pressures in the key North American market.

Dr Reddy's Laboratories witnessed a sharp decline in its stock price on Wednesday, January 24, following its Q3 FY25 earnings announcement. The stock plummeted 7% intraday, making it the top loser on the Nifty 50 index.

Dr. Reddy's Laboratories Ltd.'s profit rose 2% in the third quarter of the current financial year, but missed analysts' estimates.

Dr Reddy's Laboratories shares dropped nearly 7% on Friday after the company reported a slight increase in net profit for the third quarter, disappointing investors.

Dr Reddy’s Laboratories reports 2% increase in net profit, attributing growth to new acquisitions and product launches.

Dr Reddy's Laboratories reported a 2% increase in net profit to Rs 1,413 crore for the third quarter ending December 2024. The company's revenue surged to Rs 8,359 crore, driven by new business acquisitions and launches.

Hyderabad: Despite posting record revenues, pharma major Dr Reddy's Laboratories on Thursday reported a marginal 2% increase in consolidated profit after tax (PAT attributable to equity holders) at 1,